Mobile in Clinical Trials’ Post

Patients with rare diseases often face a challenging journey—limited treatment options, lengthy clinical trials, and prolonged drug approval processes. How can we expedite the drug approval process? Join a panel discussion led by Mike Ward, Global Head of Thought Leadership, Life Science & Healthcare at Clarivate, Rob Etherington, CEO at Clene Nanomedicine, Inc. and Neil McFarlane, CEO at Zevra Therapeutics to examine the dynamic role data might play in rare disease and personalized medicine. View the on-demand webinar to determine what companies need to be doing to address this complex and evolving field, here: https://lnkd.in/eHsQxAMw #RareDiseases #DrugDevelopment #PatientAdvocacy #RegulatoryAffairs #ClinicalTrials

IMPORTANT & RELEVANT INDUSTRY DISCUSSION @ MOBILE IN CLINICAL TRIALS - I am so honored to be part of this important panel focused on the value & ROI benefit of digital technologies in clinical trials. Now, in the post-COVID environment, in a world where there are currently over 7.2 Billion digital smartphones worldwide, where ~90% of all cellular phones are (digital) smartphones and the majority of the world’s population currently owns one, it sure seems there have been retractions in the value and adoption of digital technologies in clinical trials for traditional legacy solutions. This panel is focused on realities, value propositions and ROIs that begs the question, "What are we doing and why, or, . . . . why not?"

While survival and function are two crucial endpoints for rare diseases such as Amyotrophic lateral sclerosis (ALS), it is equally important for efficient drug development overcoming regulatory challenges. What breakthroughs are on the cusp for rare and orphan diseases that make you hopeful for patients? Join the panel discussion led by Mike Ward, Global Head of Thought Leadership, Life Science & Healthcare at Clarivate, Rob Etherington, CEO at Clene Nanomedicine, Inc. and Neil McFarlane, CEO at Zevra Therapeutics to examine the dynamic role data might play in rare disease and personalized medicine. View the on-demand webinar to determine what companies need to be doing to address this complex and evolving field, here: https://lnkd.in/eHsQxAMw #raredisease #regulatory #IRA #ALS

JUST IN: Critical Path Institute's Translational Therapeutics Accelerator (TRxA) has entered into a collaboration with Celdara Medical to identify and advance innovative therapeutics for urgent medical needs. Exciting news for the healthcare industry! #medicalresearch #collaboration #innovation #drugdevelopment #TheReportify. Share your thoughts in the comments below. To learn more and read the complete story, click on this link. https://lnkd.in/g7PHWnVT

Join our live webinar: "From Penicillin to digital therapeutics and the pace of change in life sciences: Where are the dollars flowing?" 📅 Thursday, April 4, 2024 at 10am EST | 4pm CET 🔍 Description: The life sciences industry is advancing at an unprecedented pace, from traditional remedies like penicillin to cutting-edge digital therapeutics. Join us for an engaging webinar as we delve into the changing landscape of life sciences investments. 🎯 Key Learning Objectives: ➡️ Understand current trends in life science investments ➡️ Identify high-growth categories expected in the near term (2–5 years) ➡️ Gain insights into anticipated FDA approvals for key disease states ➡️ Don't miss this opportunity to gain valuable insights and stay ahead in the rapidly evolving world of life sciences! Secure your spot now. #LifeSciences #PharmaTrends #DigitalTherapeutics #Investing #Webinar

Are you interested in ADCs with payloads beyond traditional cytotoxics and formats beyond mAbs? The 3rd Next-Generation Conjugates Summit will showcase developments in antibody-oligonucleotide, fragment-drug, bispecific-drug, antibody-steroid conjugates and other novel forms of ADCs as 𝐭𝐡𝐞 𝐨𝐧𝐥𝐲 𝐞𝐯𝐞𝐧𝐭 𝐝𝐞𝐝𝐢𝐜𝐚𝐭𝐞𝐝 𝐭𝐨 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐧𝐨𝐯𝐞𝐥 𝐩𝐚𝐲𝐥𝐨𝐚𝐝 𝐚𝐧𝐝 𝐟𝐨𝐫𝐦𝐚𝐭 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞 𝐝𝐞𝐬𝐢𝐠𝐧, 𝐞𝐬𝐭𝐚𝐛𝐥𝐢𝐬𝐡𝐢𝐧𝐠 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧, 𝐚𝐧𝐝 𝐬𝐭𝐫𝐞𝐚𝐦𝐥𝐢𝐧𝐢𝐧𝐠 𝐂𝐌𝐂 𝐭𝐨 𝐞𝐱𝐩𝐚𝐧𝐝 𝐭𝐡𝐞 𝐭𝐨𝐨𝐥𝐤𝐢𝐭 𝐨𝐟 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞 𝐝𝐫𝐮𝐠 𝐝𝐞𝐬𝐢𝐠𝐧 𝐚𝐧𝐝 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭. Learn from Dyne Therapeutics sharing their FORCE Platform to deliver transformative antibody-oligonucleotide conjugates for Mytonic Dystrophy 1, hear Theratechnologies Inc. discuss how their Peptide Drug Conjugate has rapid internalization and improved tumor penetration compared to traditional ADCs, AstraZeneca explore the design and preclinical activity of a Bispecific EGFR-MET targeted ADC, plus insights from another 30+ industry leading speakers. 𝐓𝐡𝐢𝐬 𝐰𝐞𝐞𝐤 𝐢𝐬 𝐚𝐥𝐬𝐨 𝐭𝐡𝐞 𝐥𝐚𝐬𝐭 𝐜𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐬𝐚𝐯𝐞 𝐨𝐧 𝐲𝐨𝐮𝐫 𝐫𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐬𝐭 𝐛𝐞𝐟𝐨𝐫𝐞 𝐭𝐡𝐞 𝐞𝐧𝐝 𝐨𝐟 𝟐𝟎𝟐𝟑, 𝐬𝐨 𝐬𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐩𝐥𝐚𝐜𝐞 𝐭𝐡𝐢𝐬 𝐰𝐞𝐞𝐤 𝐭𝐨 𝐬𝐚𝐯𝐞 𝐮𝐩 𝐭𝐨 $𝟖𝟓𝟎. See the full speaker line-up here - https://lnkd.in/edCgc8sg Register your place here - https://lnkd.in/e4JMEfKT If interested please get in touch with myself, Julia Lenkiewicz and Younis Aljebechi who can provide the relevant information and answer any questions. Looking forward to seeing as many of you in Boston next February! #adc #worldadc #antibodydrugconjugates

Our SPATIALPlex Solutions bring innovative approaches to your biomarker and clinical development programs. Spatially visualizing drug activity with unparalleled precision, Flagship Biosciences supports discovery and target engagement decisions that transcend conventional approaches and enable vivid insights to refine drug efficacy. Learn more… https://hubs.la/Q02rq17H0 #SpatialBiology #SpatialPlexSolutions #DigitalPathology #DrugDevelopment

As the biotech industry continues to evolve, the pursuit of advanced therapies for rare diseases stands at the forefront. These conditions, affecting approximately 300 million people worldwide, present a significant unmet medical need. Here are key considerations for biotech companies venturing into this critical space: 1. Scientific Validation: Rigorous validation of therapeutic targets is paramount. The cautionary tale of Alexion Pharmaceuticals’ acquisition of Wilson Therapeutics underscores the importance of mechanistic trials and copper elimination efficacy. 2. Market Access Strategy: Clinical value alone won’t suffice. A robust market access strategy, aligned with clinical endpoints, is essential. Partnerships with rare disease experts can enhance outcomes and drive commercial success. 3. Patient-Centric Approach: Patient advocacy and engagement are pivotal. Biotechs must prioritize patient needs, ensuring therapies are accessible and affordable. Regulatory approval doesn’t guarantee patient access. 4. Financial Viability: Balancing innovation with financial sustainability is challenging. Biotechs should explore funding avenues, leverage incentives, and strategically manage R&D spending. I eagerly anticipate joining forces with each of our esteemed biotech partners, embarking on a journey to revolutionize lives through groundbreaking therapies! At WEP Clinical, we offer a comprehensive array of Patient Enabling Solutions, meticulously designed to propel your asset from the laboratory to the market. Let’s forge ahead together, making a lasting impact on patients worldwide! #WEPClinical #RareDiseases #BiotechInnovation #PatientImpact #PatientAccess

With #BIO2024 taking place this week in San Diego, the life sciences community closes in on a mid-year check-in point. A time when thousands of the greatest scientific innovators from across the globe come together to take a pulse on the state of the industry, reflect on the first half of the year and predict what lies ahead. As the life sciences community comes together and looks ahead to what's needed to accelerate the development and delivery of modern therapeutics, they must move beyond traditional research spaces and large-scale manufacturing and global distribution centers. In my recent interview with @BioPharmaDive, I discuss how SmartLabs is helping to bridge the gap between traditional and modern drug development through our first-in-class, integrated offerings which combine reconfigurable lab infrastructure, operations, and scientific expertise. Read the full Q&A on BioPharmDive: https://lnkd.in/g_iYzUXe #SmartLabs #EnablingTheFutureOfScience #BioPharma #LabSolutions

🔍 Despite the evidence pointing to their enormous potential, digital endpoints are not widely used in clinical trials. However, a recently published article Journal of Clinical & Translational Science highlighting the financial benefits of leveraging digital endpoints in trials could start to swift that trend. 📚 The publication features findings from work conducted by Digital Medicine Society (DiMe), Tufts Center for the Study of Drug Development, Johnson & Johnson, Roche, Genentech, UCB, Bayer, Takeda, and MindMed. 💡 They found that digital endpoints can shorten trial phases, improve participant enrollment, and reduce costs, among other financial benefits 🔑 The key takeaway is that we must continue to advance the use of digital endpoints to enhance clinical trials, which will improve healthcare delivery. 🔗 Read our findings here: https://bit.ly/3YusSW3